Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients

• Status: Completed
• Trial end date: 2006-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the switch from tacrolimus to cyclosporine microemulsion benefits post-transplant diabetes management (in terms of glycogenic control and insulin dosage) in stable liver transplant recipients.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: Cyclosporine; Cyclosporins; Immunosuppressive Agents

Criteria

Inclusion Criteria:

• At least 4 months post-transplant

• Patients in treatment with tacrolimus

• Post-transplant diabetes treated with insulin for at least one month

Exclusion Criteria

• Known hypersensitivity to cyclosporine microemulsion

• Investigational drug within 60 days before baseline or during the study

• Patients who cannot comply with the study requirements

Other protocol-defined exclusion criteria applied